Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand

© 2019 ISPOR–The professional society for health economics and outcomes research Objective: To assess the cost-effectiveness of first-line chemotherapy regimens for non-small cell lung cancer patients in Thailand. Methods: A Markov model comprising 3 health states (progression-free survival, progres...

Full description

Saved in:
Bibliographic Details
Main Authors: Unchalee Permsuwan, Sumitra Thongprasert, Buntitabhon Sirichanchuen
Format: Journal
Published: 2020
Subjects:
Economics, Econometrics and Finance
Medicine
Pharmacology, Toxicology and Pharmaceutics
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073458329&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/68362

Similar Items